COLL COLLEGIUM PHARMACEUTICAL, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1267565 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.7%
TTM net income YoY-34.7%
TTM EPS YoY-37.9%
Revenue 3-yr CAGR14.2%
Net income 3-yr CAGR61.8%
Margins
Gross margin59.0%
Operating margin15.2%
Net margin4.7%
FCF margin41.3%
EBITDA margin15.7%
Returns
ROE13.4%
ROA2.1%
ROIC (approx.)81.3%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets85.9%
Debt / equity0.00x
Current ratio1.01x
Interest coverage1.62x
Cash quality & payout
Operating cash flow / net income8.86x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $780.57M | $631.45M | $566.77M | $463.93M | $276.87M |
| Cost of revenue | $317.31M | $254.10M | $240.60M | $254.44M | $126.25M |
| Gross profit | $463.26M | $377.34M | $326.17M | $209.49M | $150.62M |
| R&D expense | — | $0 | $0 | $3.98M | $9.45M |
| SG&A expense | $284.80M | $210.36M | $159.21M | $172.19M | $118.96M |
| Operating income | $179.64M | $169.90M | $166.96M | $33.32M | $17.63M |
| Interest expense | $82.31M | $73.97M | $83.34M | $63.21M | $21.01M |
| Pretax income | $92.62M | $98.57M | $75.73M | -$28.85M | -$3.37M |
| Income tax | $29.75M | $29.38M | $27.58M | -$3.85M | -$74.89M |
| Net income | $62.87M | $69.19M | $48.16M | -$25.00M | $71.52M |
| EBITDA | $183.82M | $173.75M | $170.46M | $36.00M | $19.36M |
| EPS (basic) | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 |
| EPS (diluted) | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 |
| Weighted avg. shares (diluted) | 39.70M | 40.42M | 41.79M | 33.83M | 41.05M |
| Balance sheet | |||||
| Cash & equivalents | $231.25M | $96.61M | $238.95M | $176.24M | $188.97M |
| Short-term investments | $155.43M | $92.20M | $71.60M | $0 | — |
| Receivables | $211.33M | $228.54M | $179.53M | $183.12M | $105.84M |
| Inventory | $40.91M | $35.56M | $32.33M | $46.50M | $17.39M |
| Current assets | $691.41M | $482.26M | $537.60M | $419.99M | $315.54M |
| PP&E, net | $12.01M | $14.33M | $15.98M | $19.52M | $19.49M |
| Goodwill | $145.93M | $162.33M | $133.86M | $133.69M | — |
| Intangibles | $669.51M | $891.40M | $421.71M | $567.47M | $268.72M |
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.08M |
| Current liabilities | $440.03M | $509.51M | $457.92M | $433.73M | $279.57M |
| Total liabilities | $1.36B | $1.43B | $947.88M | $979.29M | $489.15M |
| Shareholders' equity | $301.68M | $228.84M | $195.43M | $194.84M | $202.93M |
| Shares outstanding | 31.71M | 31.44M | 31.87M | 33.85M | 33.66M |
| Cash flow statement | |||||
| Operating cash flow | $329.32M | $204.98M | $274.75M | $124.23M | $103.56M |
| Capital expenditure | $1.74M | $1.65M | $461,000 | $1.62M | $1.94M |
| Free cash flow | $327.58M | $203.33M | $274.29M | $122.61M | $101.61M |
| Investing cash flow | -$63.53M | -$287.76M | -$70.81M | -$573.69M | -$1.94M |
| Financing cash flow | -$110.25M | -$60.60M | -$140.18M | $436.72M | -$89.30M |
| Depreciation & amortization | $4.18M | $3.86M | $3.50M | $2.68M | $1.74M |
| Stock-based compensation | $41.91M | $32.40M | $27.14M | $22.87M | $24.25M |
| Share buybacks | $25.10M | $60.02M | $75.00M | $14.06M | $47.86M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.